SEC Form 4 · accession 0001104659-16-089391
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas H Aasen
Director
Period of report
Jan 11, 2016
Accepted (ET)
Jan 12, 2016 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.56 | Jan 11, 2016 | A | 16,714 | A | — | Jan 10, 2026 | Common Stock | 16,714 | 16,714 | D |
Explanation of responses
- F1The stock option will vest in three substantially equal annual installments on January 10, 2017, 2018 and 2019, subject to Mr. Aasen's continued service on each such vesting date.